Although a relatively new term, ARC reflects supra-normal renal excretion of circulating solute [ 16], and is being increasingly recognised in the ICU environment [ 17, 18], largely as a consequence of the underlying inflammatory state and therapeutic interventions provided [ 19].
The ccRCC pathway signature is largely characterized by three major biological alterations: 1) Loss of renal function that is reflected by down-regulation of pathways related to normal renal function, such as excretion and electrolyte and ion channels.
It has been demonstrated that installation of phosphate in the duodenum of normal rats rapidly increased renal excretion of phosphate without accompanying FGF23 elevations [ 29].
In this study, for the first time, we accurately describe in surgical ICU patients with relatively normal renal function the urinary electrolyte excretion profile during the acute phase following the administration of an intravenous bolus of furosemide.
In normal mice 68Ga-siderophore showed rapid renal excretion and low blood values (0.09±0.01 %ID/g) even at a short time period (90 min) after application.
Consequently to such inhibition, in patients with normal renal function, furosemide leads to the excretion of up to 20 25 % of the filtered Na+, and, in parallel, to an alteration of urinary excretion of other main electrolytes [6].
All pathways related to normal renal function are down-regulated and include excretion, sodium ion transport, sodium ion binding, hydrogen transport, proton transport, chloride transport, and voltage-gated potassium channel activity.
In subjects with normal renal function, FCM induces increased urinary fractional excretion of phosphate, decreased 1,25- vit D levels and increased PTH levels [ 37].
Normal uptake was seen in the organs of hepatobiliary and renal excretion as well as in the pancreas and normal breast tissue in some subjects.
